Moleculin Biotech Inc is a late stage pharmaceutical development company focused on advancing novel cancer therapies. It develops drug candidates based on technologies licensed from the University of Texas MD Anderson Cancer Center. Its lead program is Annamycin a new anthracycline designed to reduce cardiotoxicity and overcome resistance. The company also maintains the WP1066 portfolio targeting STAT3 and the WP1122 targeting glycolysis.
The company generates revenue…
Moleculin Biotech Inc is a late stage pharmaceutical development company focused on advancing novel cancer therapies. It develops drug candidates based on technologies licensed from the University of Texas MD Anderson Cancer Center. Its lead program is Annamycin a new anthracycline designed to reduce cardiotoxicity and overcome resistance. The company also maintains the WP1066 portfolio targeting STAT3 and the WP1122 targeting glycolysis.
The company generates revenue primarily through licensing agreements milestone payments and research collaborations with academic institutions and pharmaceutical partners. It also receives grant funding for preclinical and clinical studies. No product sales have been reported to date.
Moleculin Biotech occupies a niche in the oncology biotechnology sector where it differentiates itself through proprietary drug candidates that aim to solve limitations of existing therapies such as cardiotoxicity and multidrug resistance. It faces competition from large pharmaceutical companies and other biotech firms developing treatments for acute leukemia and solid tumors. Its advantages include orphan drug designations fast track status and a strong patent portfolio covering its lead compounds through 2040.
The company works with academic medical centers research hospitals and collaborative investigators who sponsor clinical trials of its drug candidates. It also engages contract manufacturing organizations and third party vendors for production and testing. Specific customer names are not disclosed in the filing.